Loxo Oncology, a biotech developing small molecule therapeutics to treat solid tumors, announced terms for its IPO on Monday. The Stamford, CT-based company plans to raise $57 million by offering 4.4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, it would command a fully diluted market value of $211 million.
Loxo Oncology, which was founded in 2013, plans to list on the NASDAQ under the symbol LOXO. Cowen & Company and Stifel are the joint bookrunners on the deal. It is expected to price during the week of July 28, 2014.
